Six children received etoposide as the single agent for treatment of Langerhans cell histiocytosis (LCH; histiocytosis X). Five were less than 2 years old at diagnosis. All had multiorgan involvement; one had liver and pulmonary dysfunction. Two infants also had clinical signs of immune deficiency.
The treatment of advanced histiocytosis- X with sequential hemibody irradiation
β Scribed by Thomas W. Griffin
- Publisher
- John Wiley and Sons
- Year
- 1977
- Tongue
- English
- Weight
- 177 KB
- Volume
- 39
- Category
- Article
- ISSN
- 0008-543X
No coin nor oath required. For personal study only.
β¦ Synopsis
A patient with systemic histiocytosis was treated with hemibody irradiation, vincristine, and prednisone. The patient died of an extensive peripheral neuropathy. An autopsy revealed gross histiocytosis-X involvement of the unirradiated tissues, and no evidence of disease within the field of irradiation. A treatment protocol employing sequential hemibody irradiation is discussed.
π SIMILAR VOLUMES
Viana et al. [I] described their experience with etoposide (VP-16) as initial therapy in the management of patients with Langerhans cell histiocytosis (LCH). However, caution should be used in advocating the use of an epipodophyllotoxin as the "drug of choice" for the treatment of this disorder. Alt
We have carried out a randomized phase Ill study in 105 patients with advanced nonsmall cell lung cancer, comparing a fourdrug cisplatin-mitomycin-based combination chemotherapy regimen t o sequential single-agent therapy. The combination chemotherapy regimen consisted of mitomycin C (10 mg/m2), vin
ide combined with full dose doxorubicin chemotherapy supported with peripheral blood stem cells (PBSC) and granulocyte-colony stimulating factor (G-CSF) in